|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue | ||
| License | ||
| Collaboration | ||
| Total revenue | ||
| Operating expenses: | ||
| Research and development expenses, including related party expenses of $1,144 and $912 for the years ended December 31, 2025 and 2024, respectively | ||
| General and administrative expenses | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income (expense): | ||
| Gain on bargain purchase | ||
| Interest income | ||
| Change in fair value of derivative liability | ||
| Other income (expenses), net | ||
| Total other income (expense), net | ||
| Net loss before income taxes | ||
| Income tax benefit | ||
| Net loss | ||
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on marketable securities, net | ||
| Total comprehensive loss | ||
| Net loss per share attributable to common stockholders, basic | ||
| Net loss per share attributable to common stockholders, diluted | ||
| Weighted-average shares of common stock outstanding, basic | ||
| Weighted-average shares of common stock outstanding, diluted |
Loading...
